菌 (Enterococcus faecium) R-026与细菌 (Bacillus subtilis) R-179结合,可以缓解高胆固醇血症,并调节C57BL/6小鼠的肠道微生物群
Jinli Huang1,2, Yafang Xu1, Minghao Wang1
1Department of Microecology, Dalian Medical University, 116044, Dalian, China.
FEMS microbiology letters
|November 14, 2023
概括
活组合的Bacillus subtilis R-179和Enterococcus faecium R-026 (LCBE) 益生菌通过降低胆固醇和改善肠道微生物群,有效治疗小鼠的高胆固醇血症. 这表明LCBE.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 益生菌显示出通过降低胆固醇来管理轻度高胆固醇血症的潜力.
- 以前的研究表明,益生菌通过调节肠道微生物群来改善脂质不良症.
- 关于专门针对高胆固醇血症的益生菌作用的研究有限.
研究的目的:
- 研究活体结合B. subtilis R-179和E. faecium R-026 (LCBE) 对高胆固醇血症的治疗作用.
- 在小鼠模型中评估LCBE对脂质概况,肝脏健康和肠道微生物群的影响.
主要方法:
- 在使用高胆固醇饮食的C57BL/6小鼠中诱导高胆固醇血症.
- 小鼠在5周内接受了不同剂量的LCBE或阿托瓦斯塔丁.
- 分析了血清脂质水平,肝硬化,脂肪细胞大小和肠道微生物群组成.
主要成果:
- 高剂量的LCBE显著降低了总胆固醇 (TC),LDL-C和脂多糖 (LPS) 水平.
- 服用LCBE改善了肝硬化症,并减少了脂肪细胞的扩大.
- LCBE调节了肠道微生物群的多样性,并改变了特定细菌系的丰富性,与改善的脂质配置相关.
结论:
- 通过改善脂质积累和炎症,LCBE在高胆固醇血症中表现出治疗作用.
- 该机制涉及肠道微生物群的调节,减少有害细菌群.
- 作为治疗高胆固醇血症的临床候选者,LCBE显示出前景.
相关概念视频
01:27Microbiota of the Large Intestine
The large intestine hosts the most densely populated microbial ecosystem in the human body. This complex community primarily consists of anaerobic bacteria, with Bacillota (formerly Firmicutes) and Bacteroidota (formerly Bacteroidetes) as the predominant groups. The distribution of these microbes varies along different sections of the large intestine, influenced by local environmental factors such as oxygen availability and nutrient composition.The cecum, located at the beginning of the large...
01:21Microbiota Modulation by Antibiotics
Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...